Lacosamida Vivanta

Lacosamide, the active ingredient in Lacosamida Vivanta, is an anticonvulsant presented as an intravenous solution for intravenous use. It is indicated for the treatment of partial‑onset seizures and is employed as adjunctive therapy in patients with epilepsy.

GNH USA supplies Lacosamida Vivanta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with EU GMP standards and is sourced from reputable European manufacturers. Its distribution network ensures reliable delivery across multiple continents.

Lacosamide is used in the management of seizure disorders, particularly focal epilepsy.

Partial‑onset seizures: reduces the frequency and severity of seizure episodes when added to existing therapy. Adjunctive therapy for epilepsy: enhances overall seizure control in patients already receiving antiepileptic drugs. Focal epilepsy: provides additional seizure suppression for patients with focal seizure types.

Lacosamide may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness - Nausea - Headache - Fatigue - Blurred vision - Somnolence

Serious or Rare Side Effects: - PR‑interval prolongation or other cardiac arrhythmias - Severe skin reactions such as Stevens‑Johnson syndrome - Respiratory depression - Elevated liver enzymes - Suicidal thoughts or behavior - Anaphylactic reactions

When using Lacosamide, several safety considerations should be observed to minimize risk.

Cardiac monitoring: obtain baseline ECG and monitor for PR‑interval prolongation. Renal impairment: adjust dose in patients with severe renal dysfunction. Hepatic dysfunction: monitor liver enzymes during therapy. Discontinuation: taper the dose rather than abrupt cessation to avoid seizure exacerbation. Pregnancy and lactation: use only if potential benefit justifies potential risk, as data are limited. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lacosamide can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Co‑administration with strong CYP3A4 inducers (e.g., carbamazepine) may reduce lacosamide plasma levels. - Concurrent use with other sodium‑channel blockers can increase central nervous system depression. - Combination with QT‑prolonging agents may heighten the risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Oral contraceptives may become less effective; additional contraceptive measures are advised. - Use with other antiepileptic drugs may require dose adjustments based on therapeutic response. - Alcohol consumption can enhance sedative effects, warranting caution.